Date of first authorisation/renewal of the authorisationStart typing to retrieve search suggestions. Monitoring of glucose levels is recommended.Gemfibrozil may potentiate the effects of coumarin type vitamin K antagonist anticoagulants such as warfarin, acenocoumarol, or phenprocoumon.
dabrafenib, enzalutamide, loperamide, montelukast, repaglinide, rosiglitazone, pioglitazone, dasabuvir, selexipag and paclitaxel).
Lopid is used together with diet to treat very high cholesterol and triglyceride levels in people with pancreatitis.
exercise, weight reduction) for the following: - Treatment of severe hypertriglyceridaemia with or without low HDL cholesterol.
Lopid 600 mg is a white oval film-coated tablet. Symptomatic supportive measures should be taken if overdose occurs.Pharmacotherapeutic group: Serum-lipid lowering agentGemfibrozil is a non-halogenated phenoxypentanoic acid. Symptoms reported with overdosage were abdominal cramps, abnormal LFT's, diarrhea, increased CPK, joint and muscle pain, nausea and vomiting. Gemfibrozil belongs to the class of medications known as fibrates. After administration of 600 mg twice daily a CVolume of distribution at steady state is 9-13 L. The plasma protein binding of gemfibrozil and its main metabolite are at least 97%.Gemfibrozil undergoes oxidation of a ring methyl group to form successively a hydroxymethyl and a carboxyl metabolite (the main metabolite).
Concomitant administration of gemfibrozil with bexarotene is not recommended.
The interaction profile of gemfibrozil is complex resulting in increased exposure of many medicinal products if administered concomitantly with gemfibrozil.Gemfibrozil potently inhibits CYP2C8, CYP2C9, CYP2C19, CYP1A2, and UDP glucuronyltransferase (UGTA1 and UGTA3) enzymes and also inhibits organic anion-transporting polypeptide 1B1 (OATP1B1) (see section 4.5). We comply with the HONcode standard for trustworthy health information - Administration of the products two hours or more apart is recommended.Risk of myopathy and rhabdomyolysis may be increased with concomitant administration of colchicine and gemfibrozil. Glucuronidation to gemfibrozil 1-O-β-glucuronide is another important elimination pathway for gemfibrozil in man.The enzymes involved in the metabolism of gemfibrozil are not known. Six percent of the dose is found in faeces. Gemfibrozil has also been reported to influence the pharmacokinetics of simvastatin, lovastatin, pravastatin and rosuvastatin. 4.5 Interaction with other medicinal products and other forms of interaction6.6 Special precautions for disposal and other handling9. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App store.Overdose has been reported. - Primary hypercholesterolaemia when a statin is contraindicated or not tolerated.
Gemfibrozil caused an almost 3-fold increased in AUC of simvastatin acid possibly due to inhibition of glucoronidation via UGTA1 and UGTA3, and a 3-fold increase in pravastatin AUC which may be due to interference with transport proteins. exercise, weight reduction) for the following: - Treatment of severe hypertriglyceridaemia with or without low … Clinical and biological monitoring are recommended, especially at the start of combined treatment.Gemfibrozil is highly bound to plasma proteins and there is potential for displacement interactions with other drugs.There are no adequate data on use of Lopid in pregnant women. This metabolite has a low activity compared to the mother compound gemfibrozil and an elimination half-life of approximately 20 hours. This information is intended for use by health professionalsLopid 300mg: fine white powder contained in hard gelatine capsule with a white opaque body and a maroon opaque cap imprinted 'Lopid 300' on each capsule halfLopid is indicated as an adjunct to diet and other non-pharmacological treatment (e.g.
These adverse reactions do not usually lead to discontinuation of the treatment.Adverse reactions are ranked according to frequency using the following convention: Very common (Bone marrow failure, severe anaemia, thrombocytopenia, leukopenia, eosinophiliaNeuropathy peripheral, paraesthesia, dizziness, somnolenceDiarrhoea, vomiting, nausea, abdominal pain constipation, flatulenceJaundice cholestatic, hepatitis, cholelithiasis, cholecystitis, hepatic function abnormalAngioedema, dermatitis exfoliative, urticaria, dermatitis, alopecia, photosensitivity reaction, pruritusRhabdomyolysis, myopathy, myositis, muscular weakness, synovitis, myalgia, arthralgia, pain in extremityHaemoglobin decreased, haematocrit decreased, white blood cell count decreased, blood creatine phosphokinase increasedReporting suspected adverse reactions after authorisation of the medicinal product is important.
Lopid may also be prescribed to people who cannot be prescribed other